FHMLS XI, L.P.'s Form 4 filing
Attovia Therapeutics, Inc. (ATTO) · filed Aug 6, 2026
- Accession no.
- 0001231919-26-000838
- Filed
- Aug 6, 2026, 5:35 PM ET
- Trade date
- Aug 6, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market purchases total $10.0M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| FHMLS XI, L.P.CIK 0001911580 | 10% Owner |
| Frazier Life Sciences XI, L.P.CIK 0001911592 | 10% Owner |
| FHMLS XI, L.L.C.CIK 0001911623 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Common Stock | CConversionAcquired | +1,749,192 | –F1 | – | 1,824,541 | Direct | |
| Aug 6, 2026 | Common Stock | CConversionAcquired | +1,590,175 | –F3 | – | 3,414,716 | Direct | |
| Aug 6, 2026 | Common Stock | CConversionAcquired | +1,189,940 | –F4 | – | 4,604,656 | Direct | |
| Aug 6, 2026 | Common Stock | CConversionAcquired | +961,322 | –F5 | – | 5,565,978 | Direct | |
| Aug 6, 2026 | Common Stock | PPurchaseAcquired | +588,235 | $17.00 | +$9,999,995 | 6,154,213 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Common Stock | CConversionDisposed | −1,749,192 | $0.00 | $0 | 0 | Direct | |
| Aug 6, 2026 | Common Stock | CConversionDisposed | −1,590,175 | $0.00 | $0 | 0 | Direct | |
| Aug 6, 2026 | Common Stock | CConversionDisposed | −1,189,940 | $0.00 | $0 | 0 | Direct | |
| Aug 6, 2026 | Common Stock | CConversionDisposed | −961,322 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.
Referenced by the price of 1 transaction in Table I.
- F3
The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date.
Referenced by the price of 1 transaction in Table I.
- F4
The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date.
Referenced by the price of 1 transaction in Table I.
- F5
The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 9.29:1 basis immediately upon closing of the IPO and had no expiration date.
Referenced by the price of 1 transaction in Table I.